is januvia a glp-1 drug Comparing Ozempic, Wegovy and Other Drugs Januvia for Type 2 Diabetes

[DOI] [PMC free article] [PubMed] [Google Scholar] 118.Tanne JH

Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro is the first dual-target therapy that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar levels while promoting weight loss

This underscores the need for both RWE and RCTs in parallel and reinforces the need to need to run clinical trials that reflect real-world populations, a topic explored in more detail in our blog Obesity trials on trial Some health improvement seen with GLP-1 therapy may be a direct effect of weight loss, rather than unique drug effect as seen by improvements in liver and kidney health 4

Understanding the precise mechanism by which GLP-1 agonists work is essential when evaluating whether other compounds, such as berberine, share similar pharmacological properties

The approval came after clinical trials involving 3,477 patients (2,519 on Zepbound and 958 on a placebo): Patients taking 5mg of Zepbound lost 15% of their body weight (study 1) Patients taking 10mg of Zepbound lost 19.5% (study 1) and 12.8% (study 2) of their body weight Patients taking 15mg of Zepbound lost 20.9% (study 1) and 14.7% (study 2) of their body weight Patients taking the placebo lost 3.1% (study 1) and 3.2% (study 2) of their body weight Zepbound was released to market on December 5, 2023, with six available dosages available to those with a prescription: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg